Find Funding Opportunities

Notice Change: Late Application Policy September 28, 2020, Application Due Date RFA-NS-21-002 NINDS Exploratory Grant Program Parkinson's Disease Research P20- Clinical Trial Optional)" Notice Number: NOT-NS-20-098 Key Dates Release Date: August 11, 2020 Related Announcements RFA-NS-21-002 - NINDS Exploratory Grant Program Parkinson's Disease Research P20- Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform applicants a change the late application policy the September 28, 2020, Application Due Date RFA-NS-21-002 "NINDS Exploratory Grant Program Parkinson's Disease Research P20- Clinical Trial Optional)". NINDS understands the public health emergency related the Coronavirus Disease 2019) adversely affect applicants' ability submit applications a timely manner. Late applications be accepted through 5:00 PM local time October 13, 2020, RFA-NS-21-002 "NINDS Exploratory Grant Program Parkinson's Disease Research P20- Clinical Trial Optional)". late applications submitted after October 13, 2020 be considered. cover letter citing Notice NOT-NS-20-098) be submitted, it not required. RFA modified no longer state, "No late applications be accepted this Funding Opportunity Announcement." Application Due Date(s) September 28, 2020 applications due 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due the listed date(s). late applications be accepted this Funding Opportunity Announcement. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Application Due Date(s) September 28, 2020 applications due 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due the listed date(s). Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Beth-Anne Sieber, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-5680 Email: Beth-Anne.Sieber@nih.gov

Notice Extend Eligibility Submission Diversity K22 Applications due COVID–related Disruptions Notice Number: NOT-NS-20-076 Key Dates Release Date: June 26, 2020 Related Announcements PAR-18-469 - NINDS Advanced Postdoctoral Career Transition Award Promote Diversity Neuroscience Research K22-No Independent Clinical Trials) PAR-18-468 - NINDS Advanced Postdoctoral Career Transition Award Promote Diversity Neuroscience Research K22-Clinical Trial Required) Issued National Institute Neurological Disorders Stroke NINDS) Purpose Under normal circumstances, individuals must no than 5 years cumulative postdoctoral research experience i.e. research experience subsequent completion the doctorate) the relevant due date be eligible apply the NINDS K22 Advanced Postdoctoral Career Transition Award Promote Diversity Neuroscience Research. NINDS understands COVID-19 caused major disruption the ability many individuals make progress their research. Though subject future updates, NINDS will provide least 2-receipt cycle extension roughly 8 additional months) eligibility individuals whose eligibility apply the K22, under normal eligibility rules including resubmission policy defined NOT-OD-18-197), expiring between June/July 2020 February/March 2021 inclusive these dates). addition, those normally have eligible apply the June/July 2021 receipt date have 1-receipt cycle roughly 4 months) extension. Example 1: Under normal eligibility rules, final due date which individual apply the K22 June/July 12, 2020. individual now eligible apply the K22 June/July, 2020, October/November 2020 February/March 2021. Example 2: Under normal eligibility rules, final due date which individual apply the K99/R00 February/March 12, 2021. individual now eligible apply the K22 through October/November, 2021 due dates. Example 3: Under normal eligibility rules, final due date which individual apply the K22 June/July 12, 2021. individual now eligible apply the K22 through October/November, 2021 due dates. Example 4: Under normal eligibility rules, final due date which individual apply the K22 February/March 12, 2020. individual no longer eligible the K22. Example 5: individual applied the K22 the February/March, 2020 due date and, under normal eligibility rules, still within eligibility window the June/July, 2020 due date; however, summary statement this individual released after June/July due date. Because review this applicant’s initial submission not completed time the applicant resubmit the June/July 2020 due date, individual does receive extension eligibility is longer eligible apply the K22. Inquiries Please direct inquiries to: Michelle Jones-London, Ph.D. National Institute Neurological Disorders Stroke NINDS)E-mail: NINDSDivesrityTraining@mail.nih.gov

Notice Change Eligible Activity Codes NOT-NS-20-051 Notice Special Interest: Availability Urgent Competitive Revisions Administrative Supplements Research Biological Effects the 2019 Novel Coronavirus the Nervous System" Notice Number: NOT-NS-20-074 Key Dates Release Date: 27, 2020 Related Announcements NOT-NS-20-051 - Notice Special Interest NOSI): Availability Urgent Competitive Revisions Administrative Supplements Research Biological Effects the 2019 Novel Coronavirus the Nervous System PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) PA-18-935 - Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the eligible activity codes NOT-NS-20-051 "Notice Special Interest NOSI): Availability Urgent Competitive Revisions Administrative Supplements Research Biological Effects the 2019 Novel Coronavirus the Nervous System". Effective immediately,the RF1 activity codewill added an eligible activity codeto NOT-NS-20-051, applications submitted both, PA-18-591 "Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) " PA-18-935 "Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional)". changes below bold italics. Currently Reads: Purpose Application Submission Information Applications this initiative must submitted using of following opportunity announcements the subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) PA-18-935 - Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) Applications research fall within scope an existing NINDS award should submitted through PA-18-591 Parent Admin Supp Clinical Trial Optional). Eligible activity codes limited the mechanisms listed PA-18-591. Applications research involve change the original scope an active award, still falls within mission the NINDS must apply through PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional). Eligible activity codes applications PA-18-935 limited the following mechanisms: P01, P50, R00, R01, R03, R15, R21, R33, R35, R41, R42, R43, R44, R61, U01, U19, U24, U44, U54, UG3, UH3). Modified Read: Purpose Application Submission Information Applications this initiative must submitted using of following opportunity announcements the subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) PA-18-935 - Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) Applications research fall within scope an existing NINDS award should submitted through PA-18-591 Parent Admin Supp Clinical Trial Optional). Eligible activity codes limited the mechanisms listed PA-18-591, addition the RF1 mechanism. Applications research involve change the original scope an active award, still falls within mission the NINDS must apply through PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional). Eligible activity codes applications PA-18-935 limited the following mechanisms: P01, P50, RF1, R00, R01, R03, R15, R21, R33, R35, R41, R42, R43, R44, R61, U01, U19, U24, U44, U54, UG3, UH3) other aspects this Notice Special Interest remain unchanged. Inquiries Please direct inquiries to: Please contact program officer your active award.

Notice Additional Due Date Additional Areas Focus Especially Interest” PAR-19-373 PAR-19-384, Research Biopsychosocial Factors Social Connectedness Isolation Health, Wellbeing, Illness, Recovery R01)" Notice Number: NOT-OD-20-103 Key Dates Release Date: 7, 2020 Related Announcements PAR-19-373 PAR-19-384 Issued NIH Basic Behavioral Social Science Opportunity Network OPPNET) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Center Complementary Integrative Health NCCIH) applications this funding opportunity announcement should fall within mission the Institutes/Centers. following NIH Offices co-fund applications assigned those Institutes/Centers. Office Behavioral Social Sciences Research OBSSR) Purpose purpose this Notice to add third due date” additional areas focus especially interest” PAR-19-373 PAR-19-384 Research Biopsychosocial Factors Social Connectedness Isolation Health, Wellbeing, Illness, Recovery R01 Clinical Trials Allowed/Basic Experimental Studies Humans Required),” between two current due dates, March 17, 2020 March 17, 2021. Part 1 both PARs, under Key Dates, additional application due date June 8, 2020, added. I. Part 1 Key Dates PAR-19-373 PAR-19-384 Currently Reads: Application Due Date(s): March 17, 2020; March 17, 2021 applications due 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due the listed date(s). Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. II. Part 1 Key Dates PAR-19-373 PAR-19-384 Modified this Notice) Read italics): Application Due Date(s): March 17, 2020; June 8, 2020; March 17, 2021 Scientific Merit Review: June 2020, October 2020, June 2021 applications due 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due the listed date(s). Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review: June 2020, October 2020; June 2021 Advisory Council Review: August 2020, January 2021, August 2021 III. Part 1 Key Dates PAR-19-373 PAR-19-384 Remain Unmodified: Earliest Start Date September 2020 Expiration Date March 18, 2021 Part 1 both PARs, under Part 2, Section I. Funding Opportunity Description, of Three areas focus especially interest OppNet participating NIH ICO’s include, are limited to, those listed below” appear as, 1. Effects social connectedness, connection, isolation across lifespan Affective cognitive function during aging process Contextual factors increase mitigate impact disruption isolation different developmental time points, e.g., Caregivers people dementia, severe illness, end-of-life Chronic illness limited mobility Perceived strength quality extant social connections Recent diagnosis a serious medical illness Sleep changes across lifespan e.g. during adolescence, early parenthood, menopause) Molecular markers mechanisms e.g., epigenetic modifications, gene expression, microbiome alterations, telomere attrition) associated changes social connectedness Neurobiological developmental trajectories Protective and/or risk factors associated isolation connection disruption different times development over lifespan e.g., adolescence, death mate/parent, middle-age males, onset serious medical diagnosis) Aggressive behaviors and/or risky sexual activity associated connection trajectories Mechanisms connectedness, connection, isolation Neurobiological factors Impact structure function the nervous system central, peripheral, autonomic) Impact neuroimmune neuroendocrine systems Impact neural systems associated basic affective, cognitive, social processes Importance inter-individual neural synchrony mediating moderating effects relationship trajectories Neurobiological biosignatures predict sensitivity connection disruption isolation Neurobiological processes could targets ameliorate negative effects disruption isolation Neurophysiological consequences disruption isolation substance disorders SUDs) mental illness Behavioral environmental factors consequences perceived isolation e.g., loneliness) and/or objective/observed isolation behavioral clinical outcomes adolescence adulthood Connections between social disruption/isolation specific populations and/or health/illness contexts, e.g., Sex/gender differences; sexual gender minorities Racial/ethnic differences, acculturation/bicultural adaptations contributions social integration versus isolation Autism, HIV, mental illness, recovery status, substance disorder Whether source connection disruption leads different processes outcomes E.g., Self-induced isolation versus isolation others, sense undesired loneliness vs. sought solitude Modified this Notice) Read italics): 1. Effects social connectedness, connection, isolation across lifespan Affective cognitive function during aging process Contextual factors increase mitigate impact disruption isolation different developmental time points, e.g., Caregivers people COVID-19, dementia, severe illness, end-of-life Chronic illness limited mobility Perceived strength quality extant social connections Recent diagnosis a serious medical illness including, not limited to, COVID-19 Sleep changes across lifespan e.g. during adolescence, early parenthood, menopause) Molecular markers mechanisms e.g., epigenetic modifications, gene expression, microbiome alterations, telomere attrition) associated changes social connectedness Neurobiological developmental trajectories Protective and/or risk factors associated isolation connection disruption different times development over lifespan e.g., adolescence, death mate/parent, middle-age males, onset serious medical diagnosis) Aggressive behaviors and/or risky sexual activity associated connection trajectories Mechanisms connectedness, connection, isolation Neurobiological factors Impact structure function the nervous system central, peripheral, autonomic) Impact neuroimmune neuroendocrine systems Impact neural systems associated basic affective, cognitive, social processes Importance inter-individual neural synchrony mediating moderating effects relationship trajectories Neurobiological biosignatures predict sensitivity connection disruption isolation Neurobiological processes could targets ameliorate negative effects disruption isolation Neurophysiological consequences disruption isolation substance disorders SUDs) mental illness Behavioral environmental factors consequences perceived isolation e.g., loneliness) and/or objective/observed isolation behavioral clinical outcomes adolescence adulthood Connections between social disruption/isolation specific populations and/or health/illness contexts, e.g., Sex/gender differences; sexual gender minorities Racial/ethnic differences, acculturation/bicultural adaptations contributions social integration versus isolation Autism, COVID-19, HIV, mental illness, recovery status, substance disorder Whether source connection disruption leads different processes outcomes E.g., Self-induced isolation versus isolation others, sense undesired loneliness vs. sought solitude E.g., Isolation the result preventing COVID-19 a household, preventing COVID-19 infection within household NOTE: other aspects these funding opportunity announcements PAR-19-373 PAR-19-384) remain unchanged. Inquiries Please direct inquiries to: William Elwood, PhD Office Behavioral Social Sciences Research OBSSR) Telephone: 301-402-0116 Email: william.elwood@nih.gov